An asthma treatment developed by Chippenham-based Vectura Group has earned another $2m (£1.38m) payment for the firm following publication of a clinical trial report in the US. Last month Vectura confirmed its VR315 treatment had completed a US clinical trial, sending its shares to a record high. The $2m has been triggered by completion...